

Epidemiological Differences between Colon Cancer and Rectum Cancer

Safae A¹, Moghimi Dehkordi B¹, Fatemi SR¹, Zali MR¹

Abstract

Background: Clinical and epidemiological variation was seen between the colon cancer (CC) and rectum cancer (RC). So, there is not so much data available about the epidemiological and clinicopathological differences and prognostic factors regarding to CC and CR in Iran, we aimed to perform this study.

Methods: All cases of CC and RC referred to oncology and gastroenterology wards of Taleghani General Hospital, Teheran, Iran between 2002 and 2008 were retrospectively reviewed. The research group were reviewed all medical records in the study period for collecting the required data. All patients under study were followed up until end day of 2008 (closed day) from their diagnosis.

Results: There are 856 cases of CC and 427 cases of RC. Mean survival time of CC cases was relatively higher than RC cases ($P < 0.05$). Regarding to the age at diagnosis, about 42% of CC and 42.6% of RC patients was diagnosed less than 50 years of age. Positive family history of any cancer was relatively higher in CC (40.0%) patients than RC (31.0%) patients ($P < 0.05$). significant difference was seen between CC and RC regarding to depth of tumor invasion, pathologic stage and type of first treatment. RC patient were diagnosed in more advanced pathologic stages. Regarding to histology type of tumor 75.0% of CC cases and 79.4% of RC cases was adenocarcinoma. Abdominal pain (74.4%) and blood per rectum (89.7%) were the most prevalent symptoms mentioned by patients for CC and RC, respectively. Distant metastasis, lymph node metastasis, lower BMI and poor grading of tumor was related to increased risk of death due to CC. Regarding to RC, only pathologic stage was determine as prognostic factor.

Conclusion: Results of this study emphasis that RC has a poorer prognosis comparing to CC. Up to 42 percent of patients with CC and RC are lower than 50 years of age. Patterns of CC versus RC indicate major variations in demographic and clinicopathologic characteristics that suggest possible differences in etiology and pathogenesis. So we suggest that for the analysis of cancer data, CC and RC should be investigated as separate cancers and not to be as colorectal cancer. Abdominal pain and blood per rectum should be emphasis for detection of CC and RC, respectively.

Keywords: Colon neoplasm; Rectum neoplasm; Clinical; Epidemiology; Pathology

Please cite this article as: Safae A, Moghimi Dehkordi B, Fatemi SR, Zali MR. Epidemiological Differences between Colon Cancer and Rectum Cancer. Iran J Cancer Prev. 2010; Vol3, No4, p.185-92.

1. Research Centre for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Science, Tehran, Iran

Corresponding Author:
Bijan Moghimi Dehkordi,
MSc of Epidemiology
Tel: (+98) 2122432515
Email: b_moghimi_de@yahoo.com

Received: 5 Sep. 2010
Accepted: 2 Oct. 2010
Iran J Cancer Prev 2010; 4:185-92

Introduction

Cancers of the colon and rectum occurs in high incidence rates in Europe, North America, Australia and Japan[1], whereas the incidence of these cancers are relatively low in developing countries like Iran. Recent studies have shown that the incidence and prevalence of CC and CR is increased in Iran during the last 25 years[2-4] becoming the fourth most common among all cancers[5]. The highest CC incidence rates for males and females were in Japan

and New Zealand with Age Standardized Rate (ASR) equal to 56 and 29, respectively. Also, the highest incidence rates of RC for males (ASR=27) was in Japan, Hiroshima and for females (ASR=12) in Singapore Chinese[6]. Within the USA, the incidence of CC increased by about 18% during the period 1973-1988 while the incidence of RC and mucinous adenocarcinoma in the colon remained relatively constant in this period[7]. Overall, the average rate of CC and RC amongst males in the

less developed countries is around 20% of that of the industrialized one[8].

Previous studies reported that, age standardized incidence rate of colorectal cancer in Iran has been 9.27, 9.64 and 9.90 in 2003, 2004 and 2005 in 100,000 Iranian men and 9.12, 9.47 and 9.13 in 100,000 Iranian women, respectively[9]. It is estimated that about 5,000 new cases of CC and RC are detected in Iran annually[9].

Clinical and epidemiological variation was seen between the CC and RC. Both CC and RC incidence rates are higher in males than in females[7]. While incidence rates for RC are higher amongst whites than in blacks, the incidence rates for CC are higher in blacks than in whites[7].

Approximately 60% of CC and CR in high incidence populations arise in the left colon (descending and sigmoid colon), whereas in low incidence regions there is a predominance of right-sided cases (caecum, ascending colon, hepatic flexure, transverse colon, splenic flexure) and rectum[10].

Blood loss, change in bowel habits, acute intestinal obstruction, perforation symptoms were most frequent in patients with CC[11-13], rectal bleeding while anemia, loss of body weight and abdominal pain turned out to be the predominant symptoms in patients with RC[14, 15]. Also, it showed that rectal bleeding, constipation and lower abdominal pain are the most predominant symptoms in Iranian CC and CR patients[16].

Several studies have investigated the prognostic features of the CC and CR worldwide. Dukes' stage, serum CEA level, morphology of the tumor, lymph node metastasis, depth of bowel wall invasion, was strongly associated with CC[17-20] and lymph node metastasis, depth of bowel wall invasion, differentiation of the tumor, serum CEA level, clinical stage, age at diagnosis and ethnic group were significant in RC[19, 21].

Because of, there is not so much data available about the epidemiological and clinicopathological differences and prognostic factors regarding to CC and CR in Iran, we aimed to perform this study.

Materials and Methods

All cases of CC and CR referred to oncology and gastroenterology wards of Taleghani General Hospital, Teheran, Iran between 2002 and 2008 were retrospectively reviewed. The patients were referred to our center from all over the country including private/general hospitals and clinics. This medical center is a referral university hospital (affiliated to Shahid Beheshti University of Medical

Sciences) for diagnosis, treatment and surveillance of CC and CR.

The research group were reviewed all medical records in the study period for collecting the required data. In a few number of CC and CR patients there is no information about the pathology reports and some other variables. Demographic factors (i.e. age, sex), medical records and diagnosis information (i.e. symptoms at diagnosis, family history, tumor metastasis, histologic grade of tumor, Depth of tumor invasion, Pathologic Stage, Tumor size etc.) were included in the study.

All patients under study were followed up until end day of 2008 (closed day) from their diagnosis. Deaths were confirmed through the different sources such as: vital and medical records, cemetery information and telephonic contact to relatives of patients. We encounter a few numbers of CC and CR patients wherein no information about the cause of death was obtained, but only the dates of their death were known, which we considered to be due to CC and RC.

Descriptive analysis was done for demographic and clinical features. We used the chi-square test for categorical variables and the Student's t-test for continuous variables. The mean survival of patients with CC and CR were calculated according to the Kaplan-Meier method and compared by the Log-rank test. Also, prognostic factors for the CC and rectum cancer were determined by the Cox proportional hazard model. Considering $P < 0.05$ as statistically significant, SPSS (version 13.0) software were used for data analysis.

Results

There are 856 cases of CC and 427 cases of RC. Mean survival time of CC cases was relatively higher than RC cases (Log-rank $P < 0.05$). No statistical difference was seen between the diagnostic age of CC and RC patients ($P > 0.05$). Regarding to the age at diagnosis, about 42% of CC and 42.6% of RC patients were diagnosed less than 50 years of age. A sex ratio equal to 1.46 and 1.77 was seen in CC and RC patients, respectively. Positive family history of any cancer was relatively higher in CC (40.0%) patients than RC (31.0%) patients ($P < 0.05$) (Table 1).

Table 1 shown that, significant difference was seen between CC and RC regarding to depth of tumor invasion, pathologic stage and type of first treatment ($P < 0.05$). Most of patients with CC and RC were detected in T3 depth of tumor invasion. RC patient were diagnosed in more advanced pathologic stages (stage III, 44.1%). Surgery as first treatment was done in higher percents of CC cases comparing to RC

Table 1. Demographic and clinical features of patients with CC and RC patients

	Colon cancer (%) (n=856)	Rectum cancer (%) (n=427)	P-value ¹
Mean survival(months)	101.91	67.19	0.024
Age (years) (n=1283)			
Mean \pm SD	53.8+14.3	53.3+14.6	
<50	360(42.1)	182(42.6)	0.846
\geq 50	496(57.9)	245(54.7)	
Gender(n=1283)			
Male	508(59.3)	273(63.9)	0.113
Female	348(40.7)	154(36.1)	
Family history of cancer(n=1225)			
Negative	495(60.0)	276(69.0)	0.002
Positive	330(40.0)	124(31.0)	
BMI(n=828)			
\leq 18.5	42(7.8)	25(8.7)	0.304
18.6–24.9	274(50.8)	164(56.7)	
25–29.9	179(33.2)	80(27.7)	
\geq 30	44(8.2%)	20(6.9)	
Histology type(n=1283)			
Adenocarcinoma	647(75.6)	339(79.4)	0.128
Non- adenocarcinoma	209(24.4)	88(20.6)	
Depth of tumor invasion(n=894)			
T1	12(1.9)	5(1.8)	0.003
T2	61(9.8)	51(18.6)	
T3	462(74.5)	190(69.3)	
T4	85(13.7)	28(10.2)	
Grade of tumor(n=899)			
Well	346(57.5)	156(52.5)	0.149
Moderate	200(33.2)	118(39.7)	
Poor	56(9.3)	23(7.7)	
Distant metastasis(n=617)			
Absent	396(84.4)	153(85.0)	0.861
Present	68(15.6)	27(15.0)	
Regional lymph nodes metastasis(n=853)			
N0	329(54.8)	123(48.6)	0.143
N1	199(33.2)	89(33.8)	
N2	72(12.0)	41(16.2)	
Pathologic Stage(n=906)			
I	54(8.6)	42(15.1)	0.001
II	272(43.4)	86(30.8)	
III	230(36.7)	123(44.1)	
IV	71(11.3)	28(10.0)	
First treatment(n=1267)			
Surgery	701(83.2)	277(65.3)	0.001
Other	142(16.8)	147(34.7)	
Tumor size(n=818)			
<30mm	78(13.9)	48(18.8)	0.068
\geq 30mm	485(86.1)	207(81.2)	

¹ All P-value was calculated based on χ^2 test exclude of mean survival that calculated using Log-rank test

cases ($P < 0.05$). In most cases tumor grading was well differentiated and there was no significant differences between CC and RC ($P > 0.05$) (Table 1).

We have also investigated the histology type of tumor. In 647 (75.0%) of CC cases and 339(79.4%) of RC cases histology of tumor was adenocarcinoma. Larger tumor (≥ 30 mm) was seen in CC cases

Table 2. The frequency of symptoms at diagnosis in CC and RC patients

	Colon cancer (%)	Rectum cancer(%)	P-value (χ^2 test)
Sign and symptom			
Abdominal Pain(n=1070)	537(74.4)	195(56.0)	0.001
Blood per Rectum(n=1053)	407(57.9)	314(89.7)	0.001
Anemia(n=939)	254(39.1)	80(27.7)	0.001
Weight Loss(n=1054)	431(61.0)	183(52.7)	0.011
Weakness(n=1058)	380(53.7)	157(44.9)	0.007
Change in Bowel Habit(n=1035)	453(63.9)	259(74.6)	0.001
Obstructive Symptoms(n=1006)	139(20.3)	35(10.9)	0.001
Perforation Symptoms(n=987)	26(3.9)	6(1.9)	0.097
Fever of unknown origin(n=936)	64(10.0)	22(7.5)	0.222

Table 3. Prognostic factor of CC and RC of patients using Cox proportional hazard model

Prognostic factors	Hazard ratio	95% Confidence interval	P-value
Colon			
Distant metastasis(Present)	4.93	2.51-9.69	0.001
Regional lymph nodes metastasis			
N0	Ref.	-	-
N1	1.57	0.67-1.72	0.148
N2	2.64	1.27-5.48	0.005
BMI	0.85	0.79-0.91	0.001
Grade of tumor			
Well	Ref.	-	-
Moderate	0.73	0.38-1.40	0.338
Poor	3.14	1.55-6.36	0.001
Rectum			
Pathologic Stage			
I	Ref.	-	-
II	0.62	0.12-3.05	0.552
III	1.83	0.53-6.31	0.341
IV	4.64	1.08-20.02	0.040

comparing to RC, but this deference wasn't significant. Regarding to tumor metastasis, no statistical difference was seen between CC and RC patients ($P>0.05$).

The most three symptoms in patients at diagnosis consisted of abdominal pain (74.4%), change in bowel habit (63.9%), weight loss (61.0%) in CC and blood per rectum (89.7%), change in bowel habit (74.6%) and abdominal pain (56.0%) in RC(table 2).

The prognostic factor of CC and RC of patients under study is shown in table3. Presence of distant metastasis(HR=4.93), higher regional lymph node metastasis(HR=2.64), lower BMI(HR=0.85) and poor grading of tumor(HR=3.14) was related to increased risk of death due to CC. Regarding to RC, only pathologic stage was determine as prognostic factor. RC patients that diagnosed at stage IV, have a hazard ratio equal to 4.64 for death.

Discussion

We found that RC has a poorer prognosis comparing to CC. Up to 42 percent of patients with CC and RC are lower than 50 years of age. Positive family history of any cancer was most prevalent in CC patients. RC patient were diagnosed in higher stage (III) of disease. Surgery was the most curative procedure as the first treatment in CC patients. One Nigerian study reported that there an increasing number of CC and CR cases occurring in the young as 23% occurred below age 40 years while 12.4% occurred in patients 30 years and below in their study[22]. Other reports from other parts of the world showed that 35-42% of patients with CC and CR are below age 40 years[23-26]. High proportion of the CRC in young Iranians can be explained by this fact that Iranian population is young[27]. On the other hand, genetic factors maybe play an important

role in the development of CC and RC in young patients in our country[2].

Previous study reports that patterns of CC versus RC by sex, race, and age indicate major variations in demographic characteristics that suggest possible differences in etiology, pathogenesis, or screening of cancers at the two sites[28]. It is indicated that lower CC have demographic characteristics similar to RC rather than upper CC[29]. Other data from the literature suggest that intestinal cancers may differ in genetic characteristics related to race, sex, and location in the colon[30]. Thus, the demographic characteristics of these cancers together with basic biologic evidence suggest that investigators should be looking for a different set of risk factors for cancers of the upper colon when compared with that of the rectum and sites within the lower colon.

Cheng et al. reported that rates are higher in males than females for every site, but the male/female ratio increases from the cecum through the rectum[31]. While the RC shows gradual increase in men, the tendency for peaking and stabilization could be seen in women[32]. In our study a male predominance was seen in the both of CC (m/f ratio=1.46) and RC (m/f ratio=1.77) patients.

Family history of CC and CR consistently has been shown to increase risk of CC[33-38]. It has been estimated that having a history of CC and CR in first-degree relatives results in about a twofold increase in risk of developing the disease. Few studies have evaluated the risk of having a family history of CC and CR on developing cancer of the rectum[20, 39], although it could be hypothesized that more distal tumors are less strongly associated with family history. Our study showed that CC and CR patients have a higher proportion of family history of cancer comparing to RC patients ($P<0.005$). It has been suggested that risk associated with family history of CC and CR can be altered by diet and lifestyle factors[40, 41].

Regarding to depth of tumor invasion, CC patients were detected with more invasive tumors comparing to RC cases ($P<0.05$). Statistical difference was seen among CC (stage II) and RC (stage III) cases regarding stage at diagnosis. Other results of our study show that, CC and RC patients were similar regarding to variables such as: age at diagnosis, gender, BMI, histology type, grade of tumor, distant metastasis, and regional lymph node metastasis.

Our Finding showed adenocarcinoma to be the most common cancer type in our study which is compatible to other studies conducted other part of Iran[42-45] and china[46]. Sheidan et al., reported

that colorectal adenocarcinoma has been the third most frequent cancer in Luxembourg[47].

In a Jamaican study on CC and CR, most of the tumors were well or moderately differentiated adenocarcinoma[15]. Our results are in agreement with two other reports from Iran[48, 49].

In present study, the most reported symptom was abdominal pain for CC and blood per rectum for RC. Kalavi reported that abdominal pain and rectal bleeding were the most common symptoms seen in right or left CC (99%) and RCs (94.1%) and anemia was more common in right CC cases[50]. In contrast to our results; Sarmast et al. reported that most significant signs include rectal bleeding (34%) and obstruction (26%) in their study[51]. Other study showed that Common presenting features in right CC were abdominal pain, pallor, and palpable mass; in left CC were symptoms of obstruction, and in RC predominated bleeding[52].

Most reports suggest that RC has a poorer prognosis than CC[53-55]. Base on univariate analyses of our data, RC have a poorer outcome comparing to CC (mean survival: 102 v.s 67 month, $P<0.05$). Distant metastasis, regional lymph node metastasis, lowers BMI and poor differentiation were related to poorer prognosis for CC patients. So, for RC only higher stages of tumor was leading to bad outcome in patients under study. Tominaga et al., reported that for CC, only Dukes stage was significant, whereas for RC, Dukes stage, age, location of the tumor, and serosal and venous invasion by cancer cells were prognostic factors[56]. Another study carried out by He et al., the three tumor variables identified in multivariate analysis as bearing the strongest independent effect on the 5-year survival in low and middle RC were (in order to decrease prognostic impact) venous invasion, tumor size, and TNM stages[57]. Also, Hojo et al., showed that factors greatly influencing prognosis were the presence of lymph node metastasis, the degree of invasion of the intestinal wall and the site of the primary lesion. Lymph node metastasis was an especially important prognostic factor[58]. The results of Deans et al. study, confirms that Duke's stage, patient age and tumor differentiation are still the most important clinicopathological variables in CC and CR [59].

In another study conducted in China, Xu et al., have been used univariate and multivariate analysis to determine the prognostic factors that affect on survival of CC and CR patients. By using univariate analysis, they identified that lymph node metastasis and distant metastasis were the common prognostic factors for both CC and RC. Smoking, deep

infiltration, chemotherapy and serum albumin concentration were the uncertain prognostic factors for CC. Signet-ring cell carcinoma, larger tumor size (>6 cm), deep infiltration, lack of radical surgery, and advanced TNM stage were the exclusive adverse prognostic factors for RC. Also, by using multivariate analysis based on a Cox regression model, it was identified that smoking, lymph node metastasis and serum albumin concentration were independent prognostic factors for CC; advanced TNM stage, distant metastasis and palliative surgery for RC; and vessel invasion, lymph node metastasis and urine glucose for RC under curative resections[60].

This study have some limitations for example, we didn't access to part of important data. Also, in some cases the patient's medical records were Imperfect. Generally we encounter to defective data for the reason that registration of data on cancer in our centre was incomplete.

Conclusion

In conclusion, this study emphasis that RC has a poorer prognosis comparing to CC. Up to 42 percent of patients with CC and RC are lower than 50 years of age. Patterns of CC versus RC indicate major variations in demographic and clinicopathologic characteristics that suggest possible differences in etiology and pathogenesis. So we suggest that for the analysis of cancer data, CC and RC should be investigated as separate cancers and not to be as colorectal cancer. Abdominal pain and blood per rectum should be emphasis for detection of CC and RC, respectively.

Acknowledgment

The authors are thankful to all staffs involved in obtaining interview information, and the cooperation of the participants is much appreciated. This study was supported by grants from Research Centre for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Science; Tehran, Iran.

Conflict of Interest

None to declare

Authors' Contribution

AS conceived and designed this study and interpreted the results and drafted the manuscript. BMD designed and carried out the analysis and participated in writing and revise the manuscript. SRF revised and approved the final manuscript. MRZ supervised the project. All authors read and improved the final manuscript.

References

1. Kihaprema T, Srivatanakul P. Colon and rectum cancer in Thailand: an overview. *Japanese journal of clinical oncology*. 2008 Apr; 38(4):237-43.
2. Azadeh S, Moghimi-Dehkordi B, Fatem SR, Pourhoseingholi MA, Ghiasi S, Zali MR. Colorectal cancer in Iran: an epidemiological study. *Asian Pac J Cancer Prev*. 2008; 9(1):123-6.
3. Moghimi-Dehkordi B, Safaei A, Zali MR. Prognostic factors in 1,138 Iranian colorectal cancer patients. *Int J Colorectal Dis*. 2008 Jul; 23(7):683-8.
4. Safaei A, Moghimi-dehkordi B, Fatemi S, Ghiasi S, Zali M. Pathology and Prognosis of Colorectal Cancer. *Iranian Journal of cancer prevention*. 2009; 2(3):137-41.
5. Moghimi-Dehkordi B, Safaei A, Zali MR. Comparison of colorectal and gastric cancer: survival and prognostic factors. *Saudi J Gastroenterol*. 2009 Jan; 15(1):18-23.
6. Parkin DM WS, Ferlay J, Treppe L, Thomas DB, editors. *Cancer incidence in five continents Vol. VIII. IARC scientific publications No. 155*. Lyon, France: International Agency for Research on Cancer 2002; 550-60.
7. Thomas RM, Sobin LH. Gastrointestinal cancer. *Cancer*. 1995 Jan 1; 75(1 Suppl):154-70.
8. Keshtkar A, Semnani SH, Besharat S, Aboomardani M, Abdolahi N, Roshandel GH, et al. Colorectal cancer nutritional risk factors: A population based case-control study. *Iranian Journal of Cancer Prevention*. 2010; 3(2):93-7.
9. Esna-Ashari F, Sohrabi MR, Abadi AR, Mehrabian AA, Mofid B, Bohluli M, et al. Colorectal cancer prevalence according to survival data in Iran-2007. *Iranian Journal of Cancer Prevention*. 2009; 2(1):15-8.
10. Iacopetta B. Are there two sides to colorectal cancer? *International journal of cancer*. 2002 Oct 10; 101(5):403-8.
11. Bloem RM, Zwaveling A, Stijnen T. Adenocarcinoma of the colon and rectum: a report on 624 cases. *The Netherlands journal of surgery*. 1988 Oct; 40(5):121-6.
12. Chen HS, Sheen-Chen SM. Obstruction and perforation in colorectal adenocarcinoma: an analysis of prognosis and current trends. *Surgery*. 2000 Apr; 127(4):370-6.
13. Rasul KI, Awidi AS, Mubarak AA, Al-Homsy UM. Study of colorectal cancer in Qatar. *Saudi Med J*. 2001 Aug; 22(8):705-7.
14. Saidi HS, Karuri D, Nyaim EO. Correlation of clinical data, anatomical site and disease stage in colorectal cancer. *East African medical journal*. 2008 Jun; 85(6):259-62.
15. McFarlane ME, Rhoden A, Fletcher PR, Carpenter R. Cancer of the colon and rectum in a Jamaican population: diagnostic implications of the changing frequency and subsite distribution. *The West Indian medical journal*. 2004 Jun; 53(3):170-3.
16. Shafayan B, Keyhani M. Epidemiological evaluation of colorectal cancer. *Acta Medica Iranica*. 2003; 41(3):156-60.
17. Harrison LE, Guillem JG, Paty P, Cohen AM. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate

analysis of 572 patients. *Journal of the American College of Surgeons*. 1997 Jul; 185(1):55-9.

18. Liang H, Wang XN, Wang BG, Pan Y, Liu N, Wang DC, et al. Prognostic factors of young patients with colon cancer after surgery. *World J Gastroenterol*. 2006 Mar 7; 12(9):1458-62.

19. Park YJ, Park KJ, Park JG, Lee KU, Choe KJ, Kim JP. Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. *World journal of surgery*. 1999 Jul; 23(7):721-6.

20. Wanebo HJ, Rao B, Pinsky CM, Hoffman RG, Stearns M, Schwartz MK, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. *The New England journal of medicine*. 1978 Aug 31; 299(9):448-51.

21. Du WB, Chia KS, Sankaranarayanan R, Sankila R, Seow A, Lee HP. Population-based survival analysis of colorectal cancer patients in Singapore, 1968-1992. *International journal of cancer*. 2002 May 20; 99(3):460-5.

22. Abdulkareem FB, Abudu EK, Awolola NA, Elesha SO, Rotimi O, Akinde OR, et al. Colorectal carcinoma in Lagos and Sagamu, Southwest Nigeria: a histopathological review. *World J Gastroenterol*. 2008 Nov 14; 14(42):6531-5.

23. Adekunle OO, Abioye AA. Adenocarcinoma of the large bowel in Nigerians: a clinicopathologic study. *Diseases of the colon and rectum*. 1980 Nov-Dec; 23(8):559-63.

24. Akinola DO, Arigbabu AO. Pattern and presentation of large bowel neoplasms in Nigerians. *The Central African journal of medicine*. 1994 Apr; 40(4):98-102.

25. Ojo OS, Odesanmi WO, Akinola OO. The surgical pathology of colorectal carcinomas in Nigerians. *Trop Gastroenterol*. 1992 Apr-Jun; 13(2):64-9.

26. Soliman AS, Bondy ML, Levin B, Hamza MR, Ismail K, Ismail S, et al. Colorectal cancer in Egyptian patients under 40 years of age. *International journal of cancer*. 1997 Mar 28; 71(1):26-30.

27. Ansari R, Mahdavinia M, Sadjadi A, Nouraei M, Kamangar F, Bishehsari F, et al. Incidence and age distribution of colorectal cancer in Iran: results of a population-based cancer registry. *Cancer letters*. 2006 Aug 18; 240(1):143-7.

28. Matanoski G, Tao XG, Almon L, Adade AA, Davies-Cole JO. Demographics and tumor characteristics of colorectal cancers in the United States, 1998-2001. *Cancer*. 2006 Sep 1; 107(5 Suppl):1112-20.

29. Anderson WF, Umar A, Brawley OW. Colorectal carcinoma in black and white race. *Cancer metastasis reviews*. 2003 Mar; 22(1):67-82.

30. Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. *Current opinion in oncology*. 2001 Jan; 13(1):63-9.

31. Cheng X, Chen VW, Steele B, Ruiz B, Fulton J, Liu L, et al. Subsite-specific incidence rate and stage of disease in colorectal cancer by race, gender, and age group in the United States, 1992-1997. *Cancer*. 2001 Nov 15; 92(10):2547-54.

32. Plesko I, Boyle GS, Ondrusova M, Tomasek L, Kubik A. Dominant position of colorectal cancer in Slovakia: the old-new problem for cancer control. *Neoplasma*. 2008; 55(1):10-5.

33. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. *The New England journal of medicine*. 1994 Dec 22; 331(25):1669-74.

34. Kerber RA, Slattery ML, Potter JD, Caan BJ, Edwards SL. Risk of colon cancer associated with a family history of cancer or colorectal polyps: the diet, activity, and reproduction in colon cancer study. *International journal of cancer*. 1998 Oct 5; 78(2):157-60.

35. Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: a review of the epidemiology. *Epidemiologic reviews*. 1993; 15(2):499-545.

36. Slattery ML, Kerber RA. Family history of cancer and colon cancer risk: the Utah Population Database. *Journal of the National Cancer Institute*. 1994 Nov 2; 86(21):1618-26.

37. Safaee A, Moghimi-Dehkordi B, Pourhoseingholi MA, Vahedi M, Maserat E, Ghiasi S, et al. Risk of colorectal cancer in relatives: A case control study. *Indian journal of cancer*. 2010; 47(1):27-30.

38. Moghimi Dehkordi B, Safaee A, Pourhoseingholi MA, Vahedi M, Habibi M, Pourhoseingholi A, et al. Prevalence of positive family history of colorectal cancer in the Iranian general population. *Iranian Journal of Cancer Prevention*. 2010; 3(1):28-31.

39. Newcomb PA, Taylor JO, Trentham-Dietz A. Interactions of familial and hormonal risk factors for large bowel cancer in women. *International journal of epidemiology*. 1999 Aug; 28(4):603-8.

40. Fernandez E, La Vecchia C, Talamini R, Negri E. Joint effects of family history and adult life dietary risk factors on colorectal cancer risk. *Epidemiology (Cambridge, Mass)*. 2002 May; 13(3):360-3.

41. Slattery ML, Potter JD, Ma KN, Caan BJ, Leppert M, Samowitz W. Western diet, family history of colorectal cancer, NAT2, GSTM-1 and risk of colon cancer. *Cancer Causes Control*. 2000 Jan; 11(1):1-8.

42. Jalali S, Kordjazi I, Jaladi S. Epidemiological characteristics of colorectal cancer in patients referred to Imam Khomeini Hospital during 1481-2001. *Journal of Iran University of Medical Sciences*. 2005; 11(43):723-30.

43. Molanaie N, Rahimi E, Aiobi S. Epidemiology of colorectal cancer in Kurdistan Province during 1995-99. *J Kurdistan University of Med Sci*. 2000; 17(5):22-5[In Persian].

44. Semnani S, Kazemi-Nezhad V, Abdollahi N. The epidemiological aspect of colorectal cancer in Gorgan. *J Gorgan University Med Sci*. 2003; 5(2):13-8[In Persian].

45. Pahlavan PS, Kanthan R. The epidemiology and clinical findings of colorectal cancer in Iran. *J Gastrointestin Liver Dis*. 2006 Mar; 15(1):15-9.

46. Xu AG, Jiang B, Zhong XH, Liu JH. [Clinical epidemiological characteristics of 3870 cases of colorectal cancers in Guangdong region]. *Zhonghua nei ke za zhi [Chinese journal of internal medicine]*. 2006 Jan; 45(1):9-12.

47. Scheiden R, Pescatore P, Wagener Y, Kieffer N, Capesius C. Colon cancer in Luxembourg: a national population-based data report, 1988-1998. *BMC cancer*. 2005; 5:52.
48. Saberi-Firoozi M, Kamali D, Yousefi M, Mehrabani D, Khademolhosseini F, Heydari S, et al. Clinical characteristics of colorectal cancer in Southern Iran, 2005. *Iranian Red Crescent Med J* 2007; 9(4):209-11 [In Persian].
49. Fazeli MS, Adel MG, Lebaschi AH. Colorectal carcinoma: a retrospective, descriptive study of age, gender, subsite, stage, and differentiation in Iran from 1995 to 2001 as observed in Tehran University. *Diseases of the colon and rectum*. 2007 Jul; 50(7):990-5.
50. Kalavi B. Colorectal cancer and its epidemiological aspects in Iran (2004). *Turk J Gastroenterol*. 2005 Dec; 16(4):248-9.
51. Sarmast-Shoushtari MH, Najibpoor N, Mohammadiasl J. Clinical characteristics of colorectal cancer in Razi and Golestan hospitals of Ahwaz (1992-1999). *Scientific med j*. 2002; 33(3):50-5.
52. Diaz-Plasencia J, Tantalean E, Urtecho F, Guzman C, Angulo M, Carranza C, et al. [Colorectal cancer: its clinical picture and survival]. *Rev Gastroenterol Peru*. 1996 Jan-Apr; 16(1):48-56.
53. Korenaga D, Ueo H, Mochida K, Kusumoto T, Baba H, Tamura S, et al. Prognostic factors in Japanese patients with colorectal cancer: the significance of large bowel obstruction--univariate and multivariate analyses. *Journal of surgical oncology*. 1991 Jul; 47(3):188-92.
54. Polissar L, Sim D, Francis A. Survival of colorectal cancer patients in relation to duration of symptoms and other prognostic factors. *Diseases of the colon and rectum*. 1981 Jul-Aug; 24(5):364-9.
55. Roncucci L, Fante R, Losi L, Di Gregorio C, Micheli A, Benatti P, et al. Survival for colon and rectal cancer in a population-based cancer registry. *Eur J Cancer*. 1996 Feb; 32A(2):295-302.
56. Tominaga T, Sakabe T, Koyama Y, Hamano K, Yasutomi M, Takahashi T, et al. Prognostic factors for patients with colon or rectal carcinoma treated with resection only. Five-year follow-up report. *Cancer*. 1996 Aug 1; 78(3):403-8.
57. He WJ, Wang L, Hu H, Kang SY, Qian HX, Xu FM. [Correlation of invasion, metastasis, and prognosis in low and middle rectal cancer]. *Ai zheng = Aizheng = Chinese journal of cancer*. 2002 Nov; 21(11):1222-5.
58. Hojo K, Koyama Y. Postoperative follow-up studies on cancer of the colon and rectum. *American journal of surgery*. 1982 Mar; 143(3):293-3.
59. Deans GT, Patterson CC, Parks TG, Spence RA, Heatley M, Moorehead RJ, et al. Colorectal carcinoma: importance of clinical and pathological factors in survival. *Annals of the Royal College of Surgeons of England*. 1994 Jan; 76(1):59-64.
60. Xu FY, Di MJ, Dong JK, Wang FJ, Jin YS, Zhu YM, et al. [Influence of clinical and pathomorphological parameters on prognosis in colon carcinoma and rectal carcinoma]. *Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University*. 2006 May; 35(3):303-10.